The iTrack™ Advance Advantage
For over a decade, Nova Eye’s proprietary iTrack™ canaloplasty microcatheter has been used across the globe, combining pressurized viscodilation with catheterization over the entire 360º of the conventional outflow pathway, to effectively treat more than 100,000 glaucoma patients.* Building on that success and the clinically proven effectiveness of the iTrack™ technology1,2, we are proud to introduce the next generation of iTrack™ – iTrack™ Advance.
The ground-breaking iTrack™ Advance takes the established effectiveness,1,2 accuracy and reliability of the original iTrack™ canaloplasty microcatheter, and combines it with an ergonomic, easy-to-use handheld injector.
The iTrack™ Advance has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma.
iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.